The fusion gene BCR/ABL1 is present in 95% of CML patients and ~30% in ALL (acute lymphoblastic leukemia) and has been already precisely targeted and disrupted using the CRISPR/Cas system56. Here, BCR is linked to acute lymphoblastic leukemia.